Bill > S272

This bill aims to improve the safety of infant formula by introducing new requirements for manufacturers and the Food and Drug Administration (FDA). The legislation mandates that manufacturers must notify the FDA within one business day if they detect any microorganisms during product testing, regardless of whether the formula has been distributed. Manufacturers must also promptly consult with the FDA about isolating affected products and provide detailed test results and genetic sequences. The FDA is required to respond quickly to such notifications and investigate the root cause of any contamination. Additionally, the bill requires the FDA to issue a progress report within 180 days on implementing recommendations to improve infant formula safety and supply, and to submit quarterly reports on infant formula supply chain data to key congressional committees for the next five years. The Secretary of Health and Human Services must also engage with other federal agencies and stakeholders to develop evidence-based practices for maximizing infant formula supply and safety, and submit reports at one, three, and five years after enactment detailing potential improvements in manufacturer practices and actions to enhance infant formula safety and availability.

Health and Social Services

https://www.congress.gov/bill/119th-congress/senate-bill/272/all-info